Search Result
Results for "
hypolipidemic
" in MedChemExpress (MCE) Product Catalog:
6
Isotope-Labeled Compounds
Cat. No. |
Product Name |
Target |
Research Areas |
Chemical Structure |
-
- HY-137318
-
|
Others
|
Metabolic Disease
|
BM 15766 sulfate is an inhibitor of 7-dehydrocholesterol δ7-reductase and reduces plasma cholesterol levels. BM 15766 sulfate is a hypolipidemic agent .
|
-
-
- HY-34781
-
-
-
- HY-121776
-
|
Drug Derivative
|
Cardiovascular Disease
|
Nicomol is an orally active hypolipidemic agent that can increase the high density lipoprotein cholesterol (HDL-C) level. Nicomol inhibits the rapid rise of plasma free fatty acids .
|
-
-
- HY-N1214S
-
Super Squalene-d6; trans-Squalene-d6; AddaVax-d6
|
Isotope-Labeled Compounds
|
Others
|
Squalene-d6 is a deuterium labeled Squalene. Squalene (Super Squalene) is an intermediate product in the synthesis of cholesterol, and shows several pharmacological properties such as hypolipidemic, hepatoprotective, antiatherosclerotic, cardioprotective, antioxidant, and antitumour activity .
|
-
-
- HY-119964
-
|
PPAR
|
Cardiovascular Disease
|
Cetaben is a PPARα-independent peroxisome proliferator. Cetaben is a non-fibrate hypolipidemic agent and potently reduces the concentration of cholesterol and triglycerides .
|
-
-
- HY-75625
-
4-Methoxysalicylic Acid
|
Biochemical Assay Reagents
|
Metabolic Disease
Inflammation/Immunology
|
2-Hydroxy-4-methoxybenzoic acid (4-Methoxysalicylic Acid) is a phenolic compound isolated from Hemidesmus indicus and other plants. 2-Hydroxy-4-methoxybenzoic acid exhibits anti-diabetic, hypolipidemic, hepatoprotective, and anti-snake venom activities. 2-Hydroxy-4-methoxybenzoic acid can be used in the study of diabetes and its complications, liver diseases, immune-related diseases, and snake venom poisoning .
|
-
-
- HY-125716
-
|
PPAR
|
Metabolic Disease
|
DRF-2519 (free base) is a dual activator of PPAR α and PPAR γ. DRF-2519 (free base) has antidiabetic and hypolipidemic activity .
|
-
-
- HY-121755
-
CP 18524
|
Others
|
Metabolic Disease
|
Tibric acid (CP 18524) has similar effects to those of hypolipidemic agents. Tibric acid has orally active triglyceride-lowering effects. Tibric acid can be used for research of hypertriglyceridemia .
|
-
-
- HY-167654
-
|
Others
|
Cardiovascular Disease
|
Treloxinate is an effective hypolipidemic agent. Treloxinate affects only triglyceride levels in Sprague-Dawley rats, but affects both triglyceride and cholesterol levels in Wistar rats .
|
-
-
- HY-121776R
-
|
Drug Derivative
|
Cardiovascular Disease
|
Nicomol (Standard) is the analytical standard of Nicomol. This product is intended for research and analytical applications. Nicomol is an orally active hypolipidemic agent that can increase the high density lipoprotein cholesterol (HDL-C) level. Nicomol inhibits the rapid rise of plasma free fatty acids .
|
-
-
- HY-135562
-
-
-
- HY-N6642
-
|
PPAR
Apoptosis
|
Inflammation/Immunology
Cancer
|
Ankaflavin, isolated from Monascus-Fermented red rice, is an orally active PPARγ agonist. Ankaflavin exhibits selective cytotoxic effect and induces cell death through apoptosis on cancer cells. Ankaflavin has anti-inflammatory, anti-cancer, antiatherosclerotic, and hypolipidemic effects .
|
-
-
- HY-116699
-
|
PPAR
|
Neurological Disease
Metabolic Disease
Inflammation/Immunology
|
CP-868388 free base is a potent, selective and orally active PPARα agonist with a Ki value of 10.8 nM. CP-868388 free base has little or no affinity for PPARβ (Ki of 3.47 μM) and PPARγ. CP-868388 free base has hypolipidemic and anti-inflammatory actions .
|
-
-
- HY-175005
-
|
Keap1-Nrf2
PPAR
Interleukin Related
|
Metabolic Disease
Inflammation/Immunology
|
CF-Carvacrol is an orally active lipid-lowering agent synthesized by merging the pharmacophores of Carvacrol (HY-N0711) and Clofibric acid (HY-B1415). CF-Carvacrol has a good affinity for PPAR-α. CF-Carvacrol has significant hypolipidemic activity and may exert antioxidant and anti-inflammatory activity by activating the Nrf2/HO-1 signaling pathway to reduce liver injury. CF-Carvacrol can be used for the study of CF-induced liver damage .
|
-
-
- HY-147246
-
HTD1801; BUDCA
|
Biochemical Assay Reagents
|
Metabolic Disease
|
Berberine ursodeoxycholate (HTD1801), an ionic salt of Berberine and Ursodeoxycholic acid, is an orally active and potent hypolipidemic agent. Berberine ursodeoxycholate shows significantly great reduction in liver fat content. Berberine ursodeoxycholate has a broad spectrum of metabolic activity. Berberine ursodeoxycholate can be used for the research of hyperlipidemia, non-alcoholic steatohepatitis (NASH) and diabetes .
|
-
-
- HY-N0652
-
2,3,4',5-Tetrahydroxystilbene 2-O-D-glucoside
|
ERK
NF-κB
|
Cardiovascular Disease
Neurological Disease
|
2,3,5,4'-Tetrahydroxystilbene 2-O-β-D-glucoside isolats from the roots of Polygonaceae species, inhibits the formation of 5-HETE, HHT and thromboxane B2. 2,3,5,4'-Tetrahydroxystilbene 2-O-β-D-glucoside has hypotensive, anti-ageing, anti-inflammatory, hypolipidemic, cardioprotective, and neuroprotective actions .
|
-
-
- HY-115914
-
|
LDLR
|
Others
|
Lipid-lowering agent-1 is a potent lipid-lowering agent. Lipid-lowering agent-1 has significant pharmacological effects on the inhibition of low-density lipoprotein cholesterol (LDLC) and promotion of high-density lipoprotein cholesterol (HDLC) production. Lipid-lowering agent-1 shows potent hypolipidemic effect in high-fat diet rats .
|
-
-
- HY-100144
-
-
-
- HY-B1734
-
16-DPA
|
FXR
5 alpha Reductase
Cytochrome P450
Drug Intermediate
|
Cardiovascular Disease
Cancer
|
16-Dehydropregnenolone acetate (16-DPA), a sterols compound, is an orally active 17α-hydroxylase and 5α-reductase inhibitor. 16-Dehydropregnenolone is also a potent bile acid receptor (BAR)/farnesoid X receptor (FXR) antagonist. 16-Dehydropregnenolone hypolipidemic and anticancer effects. 16-Dehydropregnenolone acetate (16-DPA) is the drug intermediate that can be used for synthesis of Dexamethasone (HY-14648) and related other steroidal pharmacophores .
|
-
-
- HY-N0926
-
Columbamin; Dehydroisocorypalmine
|
Cytochrome P450
Apoptosis
Parasite
|
Infection
Neurological Disease
Inflammation/Immunology
Cancer
|
Columbamine (Columbamin; Dehydroisocorypalmine) is an organic heterotetracyclic alkaloid extracted from plants. Columbamine is a metabolite of Berberine (HY-N0716). Columbamine inhibits the cytochrome P450 (CYP) isoform CYP3A4 (IC50 = 30.6 µM). Columbamine induces apoptosis in cancer cells. Columbamine can be used for antioxidant, anti-inflammatory, antitumor, antifungal, antiparasite, hepatoprotective, neuroprotective, hypolipidemic and hypoglycemic study .
|
-
-
- HY-N0926A
-
Columbamin chloride; Dehydroisocorypalmine chloride
|
Cytochrome P450
Apoptosis
Parasite
|
Infection
Neurological Disease
Inflammation/Immunology
Cancer
|
Columbamine (Columbamin; Dehydroisocorypalmine) chloride is an organic heterotetracyclic alkaloid extracted from plants. Columbamine chloride is a metabolite of Berberine (HY-N0716). Columbamine chloride inhibits the cytochrome P450 (CYP) isoform CYP3A4 (IC50 = 30.6 µM). Columbamine chloride induces apoptosis in cancer cells. Columbamine chloride can be used for antioxidant, anti-inflammatory, antitumor, antifungal, antiparasite, hepatoprotective, neuroprotective, hypolipidemic and hypoglycemic study .
|
-
-
- HY-100258
-
-
-
- HY-100334
-
-
-
- HY-19030
-
-
-
- HY-173217
-
|
PPAR
Phosphatase
|
Cardiovascular Disease
Metabolic Disease
|
PPARα agonist 5 is an orally available, selective partial agonist of PPARα (EC50: 3 nM). PPARα agonist 5 reduces lipid accumulation and upregulates key PPARα target genes, exerting anti-fatty liver effects. PPARα agonist 5 also exhibits significant hypolipidemic and hypoglycemic effects through partial PPARγ agonist activity and mild inhibition of protein tyrosine phosphatase 1B (PTP1B) (IC50: 79.1 μM). PPARα agonist 5 has a good safety profile and can be used in the study of type 2 diabetes with dyslipidemia .
|
-
-
- HY-N0652R
-
2,3,4',5-Tetrahydroxystilbene 2-O-D-glucoside (Standard)
|
Reference Standards
ERK
NF-κB
|
Cardiovascular Disease
Neurological Disease
|
2,3,5,4'-Tetrahydroxystilbene 2-O-β-D-glucoside (Standard) is the analytical standard of 2,3,5,4'-Tetrahydroxystilbene 2-O-β-D-glucoside. This product is intended for research and analytical applications. 2,3,5,4'-Tetrahydroxystilbene 2-O-β-D-glucoside isolats from the roots of Polygonaceae species, inhibits the formation of 5-HETE, HHT and thromboxane B2. 2,3,5,4'-Tetrahydroxystilbene 2-O-β-D-glucoside has hypotensive, anti-ageing, anti-inflammatory, hypolipidemic, cardioprotective, and neuroprotective actions .
|
-
-
- HY-N8206
-
-
-
- HY-125780
-
-
-
- HY-100144R
-
|
LDLR
Reference Standards
|
Metabolic Disease
|
Pirozadil (Standard) is the analytical standard of Pirozadil. This product is intended for research and analytical applications. Pirozadil is a hypolipidemic agent.
|
-
-
- HY-113873
-
-
-
- HY-N9725
-
16ξ-Hydroxycleroda-3,13-dien-15,16-olide
|
Dipeptidyl Peptidase
|
Metabolic Disease
|
16-Hydroxycleroda-3,13-dien-15,16-olide (16ξ-Hydroxycleroda-3,13-dien-15,16-olide; HCD), a clerodane diterpene, is a potent serine protease dipeptidyl peptidase 4 (DPP-4) inhibitor. 16-Hydroxycleroda-3,13-dien-15,16-olide down-regulates LPS-induced ERK phosphorylation in myocyte but blocks GLP-1 induced PKA expression. 16-Hydroxycleroda-3,13-dien-15,16-olide exhibits hypolipidemic, hepatoprotective, hypoglycemic efficacy .
|
-
-
- HY-124560
-
|
Others
|
Metabolic Disease
|
Lifibrol is a potent and oral activity hypolipidemic agent. Lifibrol decreases the plasma total cholesterol. Lifibrol has the potential for the research of hypercholesterolemia .
|
-
-
- HY-A0127
-
|
LDLR
|
Metabolic Disease
|
Etofibrate is the ethandiol-1,2 diester of the nicotinic and clofibric acids. Etofibrate has been shown to be a potent hypolipidemic agent in animal and human.
|
-
-
- HY-N1214
-
-
-
- HY-105008
-
(S,S)-SDG; (S,S)-LGM2605
|
Others
|
Cardiovascular Disease
Neurological Disease
Inflammation/Immunology
|
Secoisolariciresinol diglucoside ((S,S)-SDG), the main lignan in wholegrain flaxseed, is known for its beneficial effects including anti-inflammatory, antioxidant, anti-mutagenic, anti-microbial, anti-obesity, hypolipidemic, and neuroprotective effects .
|
-
-
- HY-117549
-
NO-1886
|
Lipase
|
Cardiovascular Disease
|
Ibrolipim (NO-1886) is an orally active lipoprotein lipase (LPL)-promoting agent. Ibrolipim decreases plasma triglycerides, increases high-density lipoprotein cholesterol levels. Ibrolipim has renoprotective and hypolipidemic effects .
|
-
-
- HY-N7729
-
|
Amylases
Glycosidase
|
Metabolic Disease
|
Sekikaic acid is an α-glucosidase (Glucosidase) and α-amylase (Amylases) inhibitor with hypolipidemic, antioxidant and antidiabetic activities. Sekikaic acid significantly reduces LDL, total cholesterol, and total glyceride levels and causes pancreatic beta cell regeneration .
|
-
-
- HY-W012946
-
-
-
- HY-N1214R
-
Super Squalene (Standard); trans-Squalene (Standard); AddaVax (Standard)
|
Reference Standards
Endogenous Metabolite
Reactive Oxygen Species (ROS)
Fungal
|
Infection
Cardiovascular Disease
|
Squalene (Standard) is the analytical standard of Squalene. This product is intended for research and analytical applications. Squalene (Super Squalene) is an intermediate product in the synthesis of cholesterol, and shows several pharmacological properties such as hypolipidemic, hepatoprotective, antiatherosclerotic, cardioprotective, antioxidant, and antitumour activity .
|
-
-
- HY-N0807R
-
-
-
- HY-N6993
-
|
Others
|
Metabolic Disease
|
25-O-Methylalisol A is a protostane triterpenoids isolated from Alisma orientale. The dried rhizomes of the aquatic plant Alisma orientale known as Rhizoma Alismatis is a common traditional Chinese medicine used for diuretic, anti-inflammatory, and hypolipidemic purposes, as well as the treatment of diabetes .
|
-
-
- HY-14739
-
ABT-335
|
PPAR
COX
|
Cardiovascular Disease
|
Choline Fenofibrate (ABT-335), a choline salt of Fenofibric acid (HY-B0760), releases free Fenofibric acid in the gastrointestinal tract. Fenofibric acid is a PPAR activator with antihyperlipidemic effect .
|
-
-
- HY-14739R
-
ABT-335 (Standard)
|
Reference Standards
PPAR
COX
|
Cardiovascular Disease
|
Choline Fenofibrate (Standard) is the analytical standard of Choline Fenofibrate. This product is intended for research and analytical applications. Choline Fenofibrate (ABT-335), a choline salt of Fenofibric acid (HY-B0760), releases free Fenofibric acid in the gastrointestinal tract. Fenofibric acid is a PPAR activator with antihyperlipidemic effect .
|
-
-
- HY-B0637
-
Bezafibrate
Maximum Cited Publications
9 Publications Verification
BM15075
|
PPAR
|
Cardiovascular Disease
Metabolic Disease
|
Bezafibrate is an agonist of PPAR, with EC50s of 50 μM, 60 μM, 20 μM for human PPARα, PPARγ and PPARδ, and 90 μM, 55 μM, 110 μM for murine PPARα, PPARγ and PPARδ, respectively; Bezafibrate is used as an hypolipidemic agent.
|
-
-
- HY-105008R
-
(S,S)-SDG (Standard); (S,S)-LGM2605 (Standard)
|
Reference Standards
Others
|
Cardiovascular Disease
Neurological Disease
Inflammation/Immunology
|
Secoisolariciresinol diglucoside (Standard) is the analytical standard of Secoisolariciresinol diglucoside. This product is intended for research and analytical applications. Secoisolariciresinol diglucoside ((S,S)-SDG), the main lignan in wholegrain flaxseed, is known for its beneficial effects including anti-inflammatory, antioxidant, anti-mutagenic, anti-microbial, anti-obesity, hypolipidemic, and neuroprotective effects[1][2].
|
-
-
- HY-W012946S
-
-
-
- HY-167664
-
|
Acyltransferase
|
Metabolic Disease
|
KY-455 is a novel inhibitor of acyl-CoA:cholesterol acyltransferase (ACAT). KY-455 inhibita rabbit intestinal, hepatic, macrophage and adrenal ACAT with IC50 values of 0.4, 0.9, 2.9 and 4.1 μmol/L, respectively.
|
-
-
- HY-B0637S1
-
BM15075-d4
|
Isotope-Labeled Compounds
PPAR
|
Cardiovascular Disease
Metabolic Disease
|
Bezafibrate-d4 is deuterium labeled Bezafibrate. Bezafibrate is an agonist of PPAR, with EC50s of 50 μM, 60 μM, 20 μM for human PPARα, PPARγ and PPARδ, and 90 μM, 55 μM, 110 μM for murine PPARα, PPARγ and PPARδ, respectively; Bezafibrate is used as an hypolipidemic agent.
|
-
-
- HY-113427
-
|
Endogenous Metabolite
Bcl-2 Family
Apoptosis
|
Cardiovascular Disease
Cancer
|
trans-Vaccenic acid is a naturally occurring trans fatty acid (TFA). trans-Vaccenic acid inhibits nasopharyngeal carcinoma (NPC) cell growth and induces apoptosis through the inhibition of Bad/Akt phosphorylation. trans-Vaccenic acid is a precursor for the synthesis of saturated fatty acid in the rumen and of conjugated Linoleic acid (CLA) at the tissue level. trans-Vaccenic acid exerts hypolipidemic effects in a rat model of obesity .
|
-
-
- HY-W012946R
-
Pyromucic acid (Standard)
|
Reference Standards
ATP Citrate Lyase
Acyltransferase
Endogenous Metabolite
|
Metabolic Disease
|
2-Furoic acid (Standard) is the analytical standard of 2-Furoic acid. This product is intended for research and analytical applications. 2-Furoic acid (Furan-2-carboxylic acid) is an organic compound produced through furfural oxidation . 2-Furoic acid exhibits hypolipidemic effet, lowers both serum cholesterol and serum triglyceride levels in rats .
|
-
- HY-B0637S
-
|
PPAR
|
Cardiovascular Disease
Metabolic Disease
|
Bezafibrate-d6 is the deuterium labeled Bezafibrate. Bezafibrate is an agonist of PPAR, with EC50s of 50 μM, 60 μM, 20 μM for human PPARα, PPARγ and PPARδ, and 90 μM, 55 μM, 110 μM for murine PPARα, PPARγ and PPARδ, respectively; Bezafibrate is used as an hypolipidemic agent.
|
-
- HY-B0637R
-
BM15075 (Standard)
|
Reference Standards
PPAR
|
Cardiovascular Disease
Metabolic Disease
|
Bezafibrate (Standard) is the analytical standard of Bezafibrate. This product is intended for research and analytical applications. Bezafibrate is an agonist of PPAR, with EC50s of 50 μM, 60 μM, 20 μM for human PPARα, PPARγ and PPARδ, and 90 μM, 55 μM, 110 μM for murine PPARα, PPARγ and PPARδ, respectively; Bezafibrate is used as an hypolipidemic agent.
|
-
- HY-B0637S2
-
BM15075-13C6
|
Isotope-Labeled Compounds
PPAR
|
Cardiovascular Disease
Metabolic Disease
|
Bezafibrate- 13C6 (BM15075- 13C6) is 13C labeled Bezafibrate. Bezafibrate is an agonist of PPAR, with EC50s of 50 μM, 60 μM, 20 μM for human PPARα, PPARγ and PPARδ, and 90 μM, 55 μM, 110 μM for murine PPARα, PPARγ and PPARδ, respectively; Bezafibrate is used as an hypolipidemic agent.
|
-
- HY-108571
-
|
PPAR
|
Cardiovascular Disease
Metabolic Disease
|
CP-775146 is a selective PPARα agonist (Ki of 24.5 nM) that binds strongly to the PPARα ligand. CP-775146 has no observable affinity for PPARβ and PPARγ.CP-775146 shows hypolipidemic activity. CP-775146 efficiently alleviates obesity-induced liver damage, prevents lipid accumulation by activating the liver fatty acid β-oxidation pathway .
|
-
- HY-113427R
-
|
Endogenous Metabolite
Reference Standards
Bcl-2 Family
Apoptosis
|
Cardiovascular Disease
Cancer
|
trans-Vaccenic acid (Standard) is the analytical standard of trans-Vaccenic acid (HY-113427). This product is intended for research and analytical applications. trans-Vaccenic acid is a naturally occurring trans fatty acid (TFA). trans-Vaccenic acid inhibits nasopharyngeal carcinoma (NPC) cell growth and induces apoptosis through the inhibition of Bad/Akt phosphorylation. trans-Vaccenic acid is a precursor for the synthesis of saturated fatty acid in the rumen and of conjugated Linoleic acid (CLA) at the tissue level. trans-Vaccenic acid exerts hypolipidemic effects in a rat model of obesity.
|
-
- HY-N0721
-
-
- HY-113427S
-
|
Isotope-Labeled Compounds
Endogenous Metabolite
Bcl-2 Family
Apoptosis
|
Cardiovascular Disease
Cancer
|
trans-Vaccenic acid-d13 is deuterium labeled trans-Vaccenic acid (HY-113427). trans-Vaccenic acid is a naturally occurring trans fatty acid (TFA). trans-Vaccenic acid inhibits nasopharyngeal carcinoma (NPC) cell growth and induces apoptosis through the inhibition of Bad/Akt phosphorylation. trans-Vaccenic acid is a precursor for the synthesis of saturated fatty acid in the rumen and of conjugated Linoleic acid (CLA) at the tissue level. trans-Vaccenic acid exerts hypolipidemic effects in a rat model of obesity .
|
-
- HY-N0721R
-
-
- HY-137390A
-
|
HMG-CoA Reductase (HMGCR)
|
Cardiovascular Disease
Metabolic Disease
|
(3S,5R)-Fluvastatin (potassium) is a synthetic hypolipidemic drug that inhibits HMG-CoA reductase activity. (3S,5R)-Fluvastatin (potassium) has similar antioxidative effects on copper ion-induced LDL oxidation compared to its 3R,5S enantiomer. (3S,5R)-Fluvastatin (potassium) and its metabolites demonstrate a potential to exhibit anti-atherosclerotic effects through their antioxidative activities. (3S,5R)-Fluvastatin (potassium) is clinically utilized as part of a racemic mixture for reducing plasma cholesterol levels.
|
-
- HY-N1934
-
|
Potassium Channel
HSP
|
Cardiovascular Disease
Inflammation/Immunology
Cancer
|
Dihydroberberine is a naturally occurring isoquinoline alkaloid with anti-inflammatory, anti-atherosclerotic, hypolipidemic and anti-tumor activities. Dihydroberberine inhibits the human ether-related gene (hERG) channel and significantly reduces the expression of heat shock protein 90 (Hsp90) and its interaction with hERG. Dihydroberberine also blocks the TLR4/MyD88/NF-κB signaling pathway to reduce pro-inflammatory cytokines and immunoglobulins, and has inhibitory effects on DSS (HY-116282C)-induced experimental colitis. Dihydroberberine also increases the sensitivity of lung cancer to sunitinib (HY-10255A), with synergistic efficacy .
|
-
- HY-N1934R
-
|
Reference Standards
Potassium Channel
HSP
|
Cardiovascular Disease
Inflammation/Immunology
Cancer
|
Dihydroberberine (Standard) is the analytical standard of Dihydroberberine. This product is intended for research and analytical applications. Dihydroberberine is a naturally occurring isoquinoline alkaloid with anti-inflammatory, anti-atherosclerotic, hypolipidemic and anti-tumor activities. Dihydroberberine inhibits the human ether-related gene (hERG) channel and significantly reduces the expression of heat shock protein 90 (Hsp90) and its interaction with hERG. Dihydroberberine also blocks the TLR4/MyD88/NF-κB signaling pathway to reduce pro-inflammatory cytokines and immunoglobulins, and has inhibitory effects on DSS (HY-116282C)-induced experimental colitis. Dihydroberberine also increases the sensitivity of lung cancer to sunitinib (HY-10255A), with synergistic efficacy .
|
-
Cat. No. |
Product Name |
Category |
Target |
Chemical Structure |
-
- HY-75625
-
-
-
- HY-N0652
-
2,3,4',5-Tetrahydroxystilbene 2-O-D-glucoside
|
Structural Classification
Stilbenes
Classification of Application Fields
Polygonaceae
Source classification
Other Diseases
Phenols
Polyphenols
Fallopia multiflora (Thunb.) Harald.
Plants
Disease Research Fields
|
ERK
NF-κB
|
2,3,5,4'-Tetrahydroxystilbene 2-O-β-D-glucoside isolats from the roots of Polygonaceae species, inhibits the formation of 5-HETE, HHT and thromboxane B2. 2,3,5,4'-Tetrahydroxystilbene 2-O-β-D-glucoside has hypotensive, anti-ageing, anti-inflammatory, hypolipidemic, cardioprotective, and neuroprotective actions .
|
-
-
- HY-N0926
-
-
-
- HY-N0926A
-
-
-
- HY-N0652R
-
2,3,4',5-Tetrahydroxystilbene 2-O-D-glucoside (Standard)
|
Structural Classification
Stilbenes
Polygonaceae
Source classification
Phenols
Polyphenols
Fallopia multiflora (Thunb.) Harald.
Plants
|
Reference Standards
ERK
NF-κB
|
2,3,5,4'-Tetrahydroxystilbene 2-O-β-D-glucoside (Standard) is the analytical standard of 2,3,5,4'-Tetrahydroxystilbene 2-O-β-D-glucoside. This product is intended for research and analytical applications. 2,3,5,4'-Tetrahydroxystilbene 2-O-β-D-glucoside isolats from the roots of Polygonaceae species, inhibits the formation of 5-HETE, HHT and thromboxane B2. 2,3,5,4'-Tetrahydroxystilbene 2-O-β-D-glucoside has hypotensive, anti-ageing, anti-inflammatory, hypolipidemic, cardioprotective, and neuroprotective actions .
|
-
-
- HY-N8206
-
-
-
- HY-125780
-
-
-
- HY-N1214
-
-
-
- HY-105008
-
(S,S)-SDG; (S,S)-LGM2605
|
Cardiovascular Disease
Structural Classification
Neurological Disease
Classification of Application Fields
Source classification
Lignans
Plants
Microorganisms
Linum usitatissimum Linn.
Linaceae
Phenols
Polyphenols
Phenylpropanoids
Disease Research Fields
|
Others
|
Secoisolariciresinol diglucoside ((S,S)-SDG), the main lignan in wholegrain flaxseed, is known for its beneficial effects including anti-inflammatory, antioxidant, anti-mutagenic, anti-microbial, anti-obesity, hypolipidemic, and neuroprotective effects .
|
-
-
- HY-N6642
-
-
-
- HY-N7729
-
-
-
- HY-W012946
-
-
-
- HY-N1214R
-
-
-
- HY-N0807R
-
-
-
- HY-N6993
-
-
-
- HY-105008R
-
(S,S)-SDG (Standard); (S,S)-LGM2605 (Standard)
|
Structural Classification
Microorganisms
Linum usitatissimum Linn.
Linaceae
Source classification
Lignans
Phenols
Polyphenols
Phenylpropanoids
Plants
|
Reference Standards
Others
|
Secoisolariciresinol diglucoside (Standard) is the analytical standard of Secoisolariciresinol diglucoside. This product is intended for research and analytical applications. Secoisolariciresinol diglucoside ((S,S)-SDG), the main lignan in wholegrain flaxseed, is known for its beneficial effects including anti-inflammatory, antioxidant, anti-mutagenic, anti-microbial, anti-obesity, hypolipidemic, and neuroprotective effects[1][2].
|
-
-
- HY-113427
-
-
-
- HY-W012946R
-
-
-
- HY-113427R
-
-
-
- HY-N0721
-
-
-
- HY-N0721R
-
-
-
- HY-N1934
-
-
-
- HY-N1934R
-
|
Alkaloids
Structural Classification
other families
Source classification
Plants
Isoquinoline Alkaloids
|
Reference Standards
Potassium Channel
HSP
|
Dihydroberberine (Standard) is the analytical standard of Dihydroberberine. This product is intended for research and analytical applications. Dihydroberberine is a naturally occurring isoquinoline alkaloid with anti-inflammatory, anti-atherosclerotic, hypolipidemic and anti-tumor activities. Dihydroberberine inhibits the human ether-related gene (hERG) channel and significantly reduces the expression of heat shock protein 90 (Hsp90) and its interaction with hERG. Dihydroberberine also blocks the TLR4/MyD88/NF-κB signaling pathway to reduce pro-inflammatory cytokines and immunoglobulins, and has inhibitory effects on DSS (HY-116282C)-induced experimental colitis. Dihydroberberine also increases the sensitivity of lung cancer to sunitinib (HY-10255A), with synergistic efficacy .
|
-
Cat. No. |
Product Name |
Chemical Structure |
-
- HY-N1214S
-
|
Squalene-d6 is a deuterium labeled Squalene. Squalene (Super Squalene) is an intermediate product in the synthesis of cholesterol, and shows several pharmacological properties such as hypolipidemic, hepatoprotective, antiatherosclerotic, cardioprotective, antioxidant, and antitumour activity .
|
-
-
- HY-W012946S
-
|
2-Furoic acid-d3 is the deuterium labeled 2-Furoic acid . 2-Furoic acid (Furan-2-carboxylic acid) is an organic compound produced through furfural oxidation . 2-Furoic acid exhibits hypolipidemic effet, lowers both serum cholesterol and serum triglyceride levels in rats .
|
-
-
- HY-B0637S
-
|
Bezafibrate-d6 is the deuterium labeled Bezafibrate. Bezafibrate is an agonist of PPAR, with EC50s of 50 μM, 60 μM, 20 μM for human PPARα, PPARγ and PPARδ, and 90 μM, 55 μM, 110 μM for murine PPARα, PPARγ and PPARδ, respectively; Bezafibrate is used as an hypolipidemic agent.
|
-
-
- HY-B0637S1
-
|
Bezafibrate-d4 is deuterium labeled Bezafibrate. Bezafibrate is an agonist of PPAR, with EC50s of 50 μM, 60 μM, 20 μM for human PPARα, PPARγ and PPARδ, and 90 μM, 55 μM, 110 μM for murine PPARα, PPARγ and PPARδ, respectively; Bezafibrate is used as an hypolipidemic agent.
|
-
-
- HY-B0637S2
-
|
Bezafibrate- 13C6 (BM15075- 13C6) is 13C labeled Bezafibrate. Bezafibrate is an agonist of PPAR, with EC50s of 50 μM, 60 μM, 20 μM for human PPARα, PPARγ and PPARδ, and 90 μM, 55 μM, 110 μM for murine PPARα, PPARγ and PPARδ, respectively; Bezafibrate is used as an hypolipidemic agent.
|
-
-
- HY-113427S
-
|
trans-Vaccenic acid-d13 is deuterium labeled trans-Vaccenic acid (HY-113427). trans-Vaccenic acid is a naturally occurring trans fatty acid (TFA). trans-Vaccenic acid inhibits nasopharyngeal carcinoma (NPC) cell growth and induces apoptosis through the inhibition of Bad/Akt phosphorylation. trans-Vaccenic acid is a precursor for the synthesis of saturated fatty acid in the rumen and of conjugated Linoleic acid (CLA) at the tissue level. trans-Vaccenic acid exerts hypolipidemic effects in a rat model of obesity .
|
-
Your information is safe with us. * Required Fields.
Inquiry Information
- Product Name:
- Cat. No.:
- Quantity:
- MCE Japan Authorized Agent: